NYSE:HRC - Hill-Rom Stock Price, News, & Analysis

Hill-Rom trades on the New York Stock Exchange (NYSE) under the ticker symbol "HRC."

Hill-Rom announced a quarterly dividend on Wednesday, July 18th. Stockholders of record on Friday, September 21st will be paid a dividend of $0.20 per share on Friday, September 28th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date of this dividend is Thursday, September 20th. View Hill-Rom's Dividend History.

Hill-Rom Holdings, Inc. (NYSE:HRC) posted its quarterly earnings results on Friday, July, 27th. The medical technology company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.13 by $0.02. The medical technology company had revenue of $708.60 million for the quarter, compared to analysts' expectations of $707.50 million. Hill-Rom had a net margin of 8.19% and a return on equity of 20.54%. The company's revenue was up 2.8% compared to the same quarter last year. During the same period last year, the firm posted $0.91 EPS. View Hill-Rom's Earnings History.

Hill-Rom is scheduled to release their next quarterly earnings announcement on Friday, November, 2nd 2018. View Earnings Estimates for Hill-Rom.

Hill-Rom issued an update on its fourth quarter earnings guidance on Friday, July, 27th. The company provided EPS guidance of $1.50-1.53 for the period, compared to the Thomson Reuters consensus estimate of $1.52. The company issued revenue guidance of +3-4% to ~$760.5-767.8 million, compared to the consensus revenue estimate of $756.09 million.

9 brokerages have issued 12 month price objectives for Hill-Rom's shares. Their forecasts range from $85.00 to $115.00. On average, they expect Hill-Rom's stock price to reach $100.2857 in the next twelve months. This suggests a possible upside of 9.8% from the stock's current price. View Analyst Price Targets for Hill-Rom.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hill-Rom in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hill-Rom.

Some companies that are related to Hill-Rom include ABIOMED (ABMD), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Insulet (PODD), Haemonetics (HAE), ICU Medical (ICUI), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Novocure (NVCR), Cantel Medical (CMD), NuVasive (NUVA), Merit Medical Systems (MMSI) and Tandem Diabetes Care (TNDM).

Media stories about HRC stock have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Hill-Rom earned a news and rumor sentiment score of 0.18 on Accern's scale. They also gave media headlines about the medical technology company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Hill-Rom.

Hill-Rom's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.37%), FMR LLC (3.37%), Bank of Montreal Can (2.57%), Fisher Asset Management LLC (2.13%), Renaissance Technologies LLC (1.78%) and Wells Fargo & Company MN (1.41%). Company insiders that own Hill-Rom stock include Alton Shader, Andreas G Frank, Andrew Macritchie, Carlyn D Solomon, Deborah Rasin, John J Greisch, Mary Garrett and Paul Sherwood Johnson. View Institutional Ownership Trends for Hill-Rom.

HRC stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Renaissance Technologies LLC, Wells Fargo & Company MN, Mackay Shields LLC, Russell Investments Group Ltd., Dimensional Fund Advisors LP, FMR LLC and Bernzott Capital Advisors. Company insiders that have sold Hill-Rom company stock in the last year include Alton Shader, Deborah Rasin, John J Greisch and Paul Sherwood Johnson. View Insider Buying and Selling for Hill-Rom.

HRC stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, BTIM Corp., Jennison Associates LLC, Millennium Management LLC, Marshall Wace LLP, Bank of America Corp DE, WINTON GROUP Ltd and Assenagon Asset Management S.A.. Company insiders that have bought Hill-Rom stock in the last two years include Andrew Macritchie and Mary Garrett. View Insider Buying and Selling for Hill-Rom.

Shares of HRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HRC stock can currently be purchased for approximately $91.33.

Hill-Rom has a market capitalization of $6.09 billion and generates $2.74 billion in revenue each year. The medical technology company earns $133.60 million in net income (profit) each year or $3.86 on an earnings per share basis. Hill-Rom employs 10,000 workers across the globe.

Hill-Rom's mailing address is 130 East Randolph Street Suite 1000, Chicago IL, 60601. The medical technology company can be reached via phone at 312-819-7200 or via email at [email protected]